PTC Therapeutics (NASDAQ:PTCT) Insider Sells $80,588.80 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Eric Pauwels sold 1,024 shares of PTC Therapeutics stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $78.70, for a total value of $80,588.80. Following the sale, the insider directly owned 80,141 shares in the company, valued at approximately $6,307,096.70. This trade represents a 1.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eric Pauwels also recently made the following trade(s):

• On Friday, January 9th, Eric Pauwels sold 1,722 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.41, for a total value of $133,300.02.
• On Thursday, January 8th, Eric Pauwels sold 4,602 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.50, for a total value of $352,053.00.
• On Wednesday, January 7th, Eric Pauwels sold 1,352 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total value of $104,752.96.
• On Tuesday, January 6th, Eric Pauwels sold 1,789 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $137,663.55.
• On Friday, December 19th, Eric Pauwels sold 20,508 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.26, for a total value of $1,584,448.08.
• On Wednesday, December 17th, Eric Pauwels sold 40,290 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.43, for a total transaction of $3,039,074.70.
• On Thursday, December 18th, Eric Pauwels sold 3,202 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.06, for a total transaction of $240,342.12.

PTC Therapeutics Stock Performance

Shares of PTCT stock opened at $77.29 on Thursday. The firm has a fifty day moving average of $77.07 and a 200-day moving average of $63.38. The stock has a market cap of $6.21 billion, a price-to-earnings ratio of 9.03 and a beta of 0.49. PTC Therapeutics, Inc. has a 52-week low of $35.95 and a 52-week high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.19) by $1.39. The business had revenue of $211.01 million for the quarter, compared to analysts’ expectations of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The firm’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.39) earnings per share. On average, sell-side analysts predict that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, November 5th. Jefferies Financial Group upped their target price on shares of PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Morgan Stanley reissued an “overweight” rating and set a $90.00 price target on shares of PTC Therapeutics in a report on Thursday, January 8th. Wall Street Zen upgraded shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, Wells Fargo & Company raised their price objective on shares of PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $77.27.

Institutional Investors Weigh In On PTC Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Sicart Associates LLC acquired a new stake in PTC Therapeutics in the 4th quarter valued at about $209,000. Pallas Capital Advisors LLC acquired a new stake in shares of PTC Therapeutics in the fourth quarter valued at approximately $249,000. SG Americas Securities LLC raised its position in PTC Therapeutics by 587.5% in the 4th quarter. SG Americas Securities LLC now owns 894,461 shares of the biopharmaceutical company’s stock worth $67,943,000 after purchasing an additional 764,364 shares during the last quarter. Diversified Trust Co. lifted its holdings in PTC Therapeutics by 4.9% during the 4th quarter. Diversified Trust Co. now owns 17,394 shares of the biopharmaceutical company’s stock worth $1,321,000 after buying an additional 817 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in PTC Therapeutics by 9.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 9,145 shares of the biopharmaceutical company’s stock valued at $701,000 after buying an additional 806 shares during the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.